RFA-AG-23-002: Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $275,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on March 3, 2022.
From the official notice on Grants.gov, last changed October 28, 2021. Checked November 7, 2026.
- Award ceiling$275,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- Funded byNIA
- Median yearly award$214,375
- Typical project length2.5 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under RFA-AG-23-002 were run by National Institute on Aging (NIA, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AG-23-002 in the NIH Guide.
Key dates
| Posted | October 28, 2021 |
|---|---|
| Deadline | March 3, 2022 |
| Archived by Grants.gov | April 8, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $214,375; it allows up to $275,000 per award.
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this Funding Opportunity Announcement (FOA) is to support research to identify cell-specific mechanisms in biomolecular condensate (BMC) formation and function, providing novel information for the role BMCs play in diverse cell types in the context of aging and neurobiology of Alzheimers disease (AD) or AD-related dementias (ADRD). This research should enhance our understanding of the cell-specific mechanistic role of BMCs in aging and AD/ADRD and serve as the foundation for more comprehensive etiological studies that might lead to the development of future BMC-based therapies for age-related neurodegenerative diseases.
Funded under RFA-AG-23-002 so far
NIH funded 6 projects under RFA-AG-23-002 in fiscal 2023 to 2024, at 6 institutions. The median yearly award was $214,375.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy | Dana-Farber Cancer Inst | 2024 | $267,000 |
| Single molecule biomolecular condensate analysis in neurons | University of Queensland | 2024 | $145,947 |
| Interplay between tau and PKA condensates in ADRD | University of Iowa | 2024 | $195,875 |
| Delineating the role of Matrin-3 in driving aberrant liquid-liquid phase separation that underpins ALS/FTD | Washington University | 2024 | $233,250 |
| Multilineage DAmFRET to investigate AD/ADRD protein phase behavior in neural tissue models | Stowers Institute for Medical Research | 2024 | $206,250 |
| Critical tools enabling analysis of biomolecular condensates in microglial signaling and function in aging and Alzheimer Disease | Columbia University Health Sciences | 2024 | $240,438 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AG-23-002 still open?
No. It closed on March 3, 2022.
Who can apply for Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed)?
Closed March 3, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $275,000 each.
Who has been funded under RFA-AG-23-002?
NIH RePORTER lists 6 projects funded under RFA-AG-23-002 in fiscal 2023 to 2024, at 6 institutions. The most were at Dana-Farber Cancer Inst, University of Queensland, University of Iowa.
Who has won Aging Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, The Trustees of Columbia University in the City of New York, University of Southern California. The program made 11,026 awards worth $19 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)